A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

被引:94
|
作者
Lu Gaohua [2 ]
Abduljalil, Khaled [2 ]
Jamei, Masoud [2 ]
Johnson, Trevor N. [2 ]
Rostami-Hodjegan, Amin [1 ,2 ]
机构
[1] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England
[2] Simcyp Ltd, Sheffield, S Yorkshire, England
关键词
caffeine; metoprolol; midazolam; physiologically based pharmacokinetic model; pregnancy; BLOOD-BRAIN-BARRIER; TISSUE DISTRIBUTION; COMPUTER-MODEL; CAFFEINE; WOMEN; TRANSPORTERS; METOPROLOL; POSTPARTUM; SIMULATION; MIDAZOLAM;
D O I
10.1111/j.1365-2125.2012.04363.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Pregnant women are usually not part of the traditional drug development programme. Pregnancy is associated with major biological and physiological changes that alter the pharmacokinetics (PK) of drugs. Prediction of the changes to drug exposure in this group of patients may help to prevent under- or overtreatment. We have used a pregnancy physiologically based pharmacokinetic (p-PBPK) model to assess the likely impact of pregnancy on three model compounds, namely caffeine, metoprolol and midazolam, based on the knowledge of their disposition in nonpregnant women and information from in vitro studies. Methods A perfusion-limited form of a 13-compartment full-PBPK model (Simcyp (R) Simulator) was used for the nonpregnant women, and this was extended to the pregnant state by applying known changes to all model components (including the gestational related activity of specific cytochrome P450 enzymes) and through the addition of an extra compartment to represent the fetoplacental unit. The uterus and the mammary glands were grouped into the muscle compartment. The model was implemented in Matlab Simulink and validated using clinical observations. Results The p-PBPK model predicted the PK changes of three model compounds (namely caffeine, metoprolol and midazolam) for CYP1A2, CYP2D6 and CYP3A4 during pregnancy within twofold of observed values. The changes during the third trimester were predicted to be a 100% increase, a 30% decrease and a 35% decrease in the exposure of caffeine, metoprolol and midazolam, respectively, compared with the nonpregnant women. Conclusions In the absence of clinical data, the in silico prediction of PK behaviour during pregnancy can provide a valuable aid to dose adjustment in pregnant women. The performance of the model for drugs metabolized by a single enzyme to different degrees (high and low extraction) and for drugs that are eliminated by several different routes warrants further study.
引用
收藏
页码:873 / 885
页数:13
相关论文
共 50 条
  • [41] The Effects of Puerarin on CYP2D6 and CYP1A2 Activities In Vivo
    Zheng, Jiao
    Chen, Bin
    Jiang, Bing
    Zeng, Ling
    Tang, Zhi-Rong
    Fan, Lan
    Zhou, Hong-Hao
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (02) : 243 - 246
  • [42] The effects of Puerarin on CYP2D6 and CYP1A2 activities In vivo
    Jiao Zheng
    Bin Chen
    Bing Jiang
    Ling Zeng
    Zhi-Rong Tang
    Lan Fan
    Hong-Hao Zhou
    Archives of Pharmacal Research, 2010, 33 : 243 - 246
  • [43] Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
    Grzegorzewski, Jan
    Brandhorst, Janosch
    Koenig, Matthias
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells
    Li, Hongfang
    Tang, Yunyan
    Wang, Yang
    Wei, Weipeng
    Yin, Chengchen
    Tang, Fushang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 5251 - 5258
  • [45] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    M. I. Veiga
    S. Asimus
    P. E. Ferreira
    J. P. Martins
    I. Cavaco
    V. Ribeiro
    T. N. Hai
    M. G. Petzold
    A. Björkman
    M. Ashton
    J. P. Gil
    European Journal of Clinical Pharmacology, 2009, 65 : 355 - 363
  • [46] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    Veiga, M. I.
    Asimus, S.
    Ferreira, P. E.
    Martins, J. P.
    Cavaco, I.
    Ribeiro, V.
    Hai, T. N.
    Petzold, M. G.
    Bjorkman, A.
    Ashton, M.
    Gil, J. P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 355 - 363
  • [47] Effect of rivoceranib administered as 200 mg once daily on the pharmacokinetics of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 substrates
    Jang, Seong
    Wei, Xiaohui
    Meng, Xianzhang
    Reitano, Joseph
    Urity, Vinoo
    Park, Cheol Hee
    Strickland, Bill
    Lee, Grace
    Nguyen, David
    CANCER RESEARCH, 2024, 84 (07)
  • [48] Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping
    Kashuba, ADM
    Nafziger, AN
    Kearns, GL
    Leeder, JS
    Gotschall, R
    Rocci, ML
    Kulawy, RW
    Beck, DJ
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) : 257 - 268
  • [49] Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes
    Lim, HK
    Duczak, N
    Brougham, L
    Elliot, M
    Patel, K
    Chan, K
    DRUG METABOLISM AND DISPOSITION, 2005, 33 (08) : 1211 - 1219
  • [50] Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6
    Damkier, P
    Brosen, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) : 199 - 209